Management of Antithrombotic Drugs before Elective Spine Surgery: A Nationwide Web-Based Questionnaire Survey in Japan
Introduction: The number of patients on antithrombotic drugs for coronary heart disease or cerebrovascular disease has been increasing with the aging of society. We occasionally need to decide whether to continue or discontinue antithrombotic drugs before spine surgery. The purpose of this study is to understand the current perioperative management of antithrombotic drugs before elective spine surgery in Japan. Methods: In 2021, members of the Japanese Society for Spine Surgery and Related Research (JSSR) were asked to complete a web-based questionnaire survey that included items concerning the respondents' surgical experience, their policy regarding discontinuation or continuation of antithrombotic drugs, their reasons for decisions concerning the management of antithrombotic drugs, and their experience of perioperative complications related to the continuation or discontinuation of these drugs. Results: A total of 1,181 spine surgeons returned completed questionnaires, giving a response rate of 32.0%. JSSR board-certified spine surgeons comprised 75.1% of the respondents. Depending on the management policy regarding antithrombotic drugs for each comorbidity, approximately 73% of respondents discontinued these drugs before elective spine surgery, and about 80% also discontinued anticoagulants. Only 4%-5% of respondents reported continuing antiplatelet drugs, and 2.5% reported continuing anticoagulants. Among the respondents who discontinued antiplatelet drugs, 20.4% reported having encountered cerebral infarction and 3.7% reported encountering myocardial infarction; among those who discontinued anticoagulants, 13.6% reported encountering cerebral embolism and 5.4% reported encountering pulmonary embolism. However, among the respondents who continued antiplatelet drugs and those who continued anticoagulants, 26.3% and 27.2%, respectively, encountered an unexpected increase in intraoperative bleeding, and 10.3% and 8.7%, respectively, encountered postoperative spinal epidural hematoma requiring emergency surgery. Conclusions: Our findings indicate that, in principle, <70% of JSSR members discontinue antithrombotic drugs before elective spine surgery. However, those with a discontinuation policy have encountered thrombotic complications, while those with a continuation policy have encountered hemorrhagic complications..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Spine Surgery and Related Research - 7(2023), 5, Seite 428-435 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fumitake Tezuka [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Anticoagulants |
|---|
| doi: |
10.22603/ssrr.2023-0015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ091910641 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ091910641 | ||
| 003 | DE-627 | ||
| 005 | 20240412110108.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.22603/ssrr.2023-0015 |2 doi | |
| 035 | |a (DE-627)DOAJ091910641 | ||
| 035 | |a (DE-599)DOAJd6b75559a7244ee1b8e49a7bacd7899f | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RD1-811 | |
| 100 | 0 | |a Fumitake Tezuka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of Antithrombotic Drugs before Elective Spine Surgery: A Nationwide Web-Based Questionnaire Survey in Japan |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction: The number of patients on antithrombotic drugs for coronary heart disease or cerebrovascular disease has been increasing with the aging of society. We occasionally need to decide whether to continue or discontinue antithrombotic drugs before spine surgery. The purpose of this study is to understand the current perioperative management of antithrombotic drugs before elective spine surgery in Japan. Methods: In 2021, members of the Japanese Society for Spine Surgery and Related Research (JSSR) were asked to complete a web-based questionnaire survey that included items concerning the respondents' surgical experience, their policy regarding discontinuation or continuation of antithrombotic drugs, their reasons for decisions concerning the management of antithrombotic drugs, and their experience of perioperative complications related to the continuation or discontinuation of these drugs. Results: A total of 1,181 spine surgeons returned completed questionnaires, giving a response rate of 32.0%. JSSR board-certified spine surgeons comprised 75.1% of the respondents. Depending on the management policy regarding antithrombotic drugs for each comorbidity, approximately 73% of respondents discontinued these drugs before elective spine surgery, and about 80% also discontinued anticoagulants. Only 4%-5% of respondents reported continuing antiplatelet drugs, and 2.5% reported continuing anticoagulants. Among the respondents who discontinued antiplatelet drugs, 20.4% reported having encountered cerebral infarction and 3.7% reported encountering myocardial infarction; among those who discontinued anticoagulants, 13.6% reported encountering cerebral embolism and 5.4% reported encountering pulmonary embolism. However, among the respondents who continued antiplatelet drugs and those who continued anticoagulants, 26.3% and 27.2%, respectively, encountered an unexpected increase in intraoperative bleeding, and 10.3% and 8.7%, respectively, encountered postoperative spinal epidural hematoma requiring emergency surgery. Conclusions: Our findings indicate that, in principle, <70% of JSSR members discontinue antithrombotic drugs before elective spine surgery. However, those with a discontinuation policy have encountered thrombotic complications, while those with a continuation policy have encountered hemorrhagic complications. | ||
| 650 | 4 | |a antiplatelet drugs | |
| 650 | 4 | |a anticoagulants | |
| 650 | 4 | |a elective spine surgery | |
| 650 | 4 | |a perioperative complications | |
| 650 | 4 | |a postoperative spinal epidural hematoma | |
| 653 | 0 | |a Surgery | |
| 700 | 0 | |a Toshinori Sakai |e verfasserin |4 aut | |
| 700 | 0 | |a Shiro Imagama |e verfasserin |4 aut | |
| 700 | 0 | |a Hiroshi Takahashi |e verfasserin |4 aut | |
| 700 | 0 | |a Masashi Takaso |e verfasserin |4 aut | |
| 700 | 0 | |a Toshimi Aizawa |e verfasserin |4 aut | |
| 700 | 0 | |a Koji Otani |e verfasserin |4 aut | |
| 700 | 0 | |a Shinya Okuda |e verfasserin |4 aut | |
| 700 | 0 | |a Satoshi Kato |e verfasserin |4 aut | |
| 700 | 0 | |a Tokumi Kanemura |e verfasserin |4 aut | |
| 700 | 0 | |a Yoshiharu Kawaguchi |e verfasserin |4 aut | |
| 700 | 0 | |a Hiroaki Konishi |e verfasserin |4 aut | |
| 700 | 0 | |a Kota Suda |e verfasserin |4 aut | |
| 700 | 0 | |a Hidetomi Terai |e verfasserin |4 aut | |
| 700 | 0 | |a Kazuo Nakanishi |e verfasserin |4 aut | |
| 700 | 0 | |a Kotaro Nishida |e verfasserin |4 aut | |
| 700 | 0 | |a Masaaki Machino |e verfasserin |4 aut | |
| 700 | 0 | |a Naohisa Miyakoshi |e verfasserin |4 aut | |
| 700 | 0 | |a Hideki Murakami |e verfasserin |4 aut | |
| 700 | 0 | |a Yu Yamato |e verfasserin |4 aut | |
| 700 | 0 | |a Yasutsugu Yukawa |e verfasserin |4 aut | |
| 700 | 0 | |a Medical Safety Promotion Committee of The Japanese Society for Spine Surgery and Related Research |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Spine Surgery and Related Research |d The Japanese Society for Spine Surgery and Related Research, 2018 |g 7(2023), 5, Seite 428-435 |w (DE-627)DOAJ000025267 |x 2432261X |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:5 |g pages:428-435 |
| 856 | 4 | 0 | |u https://doi.org/10.22603/ssrr.2023-0015 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/d6b75559a7244ee1b8e49a7bacd7899f |z kostenfrei |
| 856 | 4 | 0 | |u https://www.jstage.jst.go.jp/article/ssrr/7/5/7_2023-0015/_pdf/-char/en |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2432-261X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2023 |e 5 |h 428-435 | ||